United Therapeutics Co. (NASDAQ:UTHR) Shares Acquired by Soleus Capital Management L.P.

Soleus Capital Management L.P. boosted its position in shares of United Therapeutics Co. (NASDAQ:UTHR) by 7.4% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 109,394 shares of the biotechnology company’s stock after buying an additional 7,500 shares during the period. United Therapeutics accounts for 2.4% of Soleus Capital Management L.P.’s investment portfolio, making the stock its 13th largest position. Soleus Capital Management L.P.’s holdings in United Therapeutics were worth $38,599,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently bought and sold shares of the company. Vident Advisory LLC boosted its position in shares of United Therapeutics by 15.0% during the 4th quarter. Vident Advisory LLC now owns 12,221 shares of the biotechnology company’s stock valued at $4,312,000 after purchasing an additional 1,596 shares in the last quarter. Two Sigma Investments LP lifted its stake in United Therapeutics by 3.0% during the fourth quarter. Two Sigma Investments LP now owns 1,773 shares of the biotechnology company’s stock valued at $626,000 after purchasing an additional 52 shares during the last quarter. State of Wyoming bought a new stake in United Therapeutics during the fourth quarter worth approximately $62,000. Siemens Fonds Invest GmbH bought a new stake in United Therapeutics during the fourth quarter worth approximately $162,000. Finally, Sherbrooke Park Advisers LLC grew its position in United Therapeutics by 64.8% in the fourth quarter. Sherbrooke Park Advisers LLC now owns 1,986 shares of the biotechnology company’s stock worth $701,000 after buying an additional 781 shares during the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.

United Therapeutics Trading Up 0.5%

Shares of NASDAQ UTHR opened at $305.35 on Monday. United Therapeutics Co. has a one year low of $264.33 and a one year high of $417.82. The business has a 50-day moving average price of $299.95 and a two-hundred day moving average price of $340.21. The firm has a market capitalization of $13.77 billion, a PE ratio of 13.41, a PEG ratio of 0.97 and a beta of 0.58.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.29 by $0.34. The business had revenue of $794.40 million during the quarter, compared to analyst estimates of $726.82 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The firm’s revenue was up 17.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $6.17 earnings per share. Research analysts anticipate that United Therapeutics Co. will post 24.48 EPS for the current year.

Insider Buying and Selling at United Therapeutics

In other news, EVP Paul A. Mahon sold 11,000 shares of United Therapeutics stock in a transaction dated Thursday, April 3rd. The stock was sold at an average price of $306.18, for a total transaction of $3,367,980.00. Following the completion of the sale, the executive vice president now directly owns 36,781 shares in the company, valued at $11,261,606.58. The trade was a 23.02% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Michael Benkowitz sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $360.76, for a total transaction of $3,607,600.00. Following the transaction, the chief operating officer now directly owns 2,577 shares in the company, valued at approximately $929,678.52. The trade was a 79.51% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 65,500 shares of company stock worth $20,765,280. 10.30% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the company. JPMorgan Chase & Co. cut their price objective on United Therapeutics from $355.00 to $350.00 and set an “overweight” rating for the company in a research report on Thursday, May 1st. HC Wainwright reaffirmed a “buy” rating and set a $425.00 target price on shares of United Therapeutics in a research report on Monday, May 5th. Bank of America raised United Therapeutics from an “underperform” rating to a “neutral” rating and set a $314.00 target price for the company in a report on Monday, April 21st. Morgan Stanley increased their price target on United Therapeutics from $346.00 to $348.00 and gave the company an “equal weight” rating in a research report on Thursday, May 1st. Finally, StockNews.com downgraded United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, May 2nd. Four analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $392.00.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.